SAN FRANCISCO (AP) — McKesson Corp. said today it will acquire US Oncology
in an all-cash deal it valued at $2.16 billion.
McKesson, a San Francisco medical company that specializes in pharmaceutical supplies, said it will buy all the outstanding
shares of US Oncology. The deal includes US Oncology’s outstanding debt, which
McKesson said will be repaid or refinanced.
US Oncology is a privately held company based in The Woodlands, Texas. It is
affiliated with more than 1,300 oncologists and works with the health care
industry in cancer research.
McKesson said the move would increase its reach into the growing
cancer-treatment industry.
“McKesson and US Oncology’s businesses are highly complementary, providing
our collective customers access to more services and solutions that will enhance
their ability to deliver advanced cancer care,” Paul Julian, McKesson executive
vice president and group president, said in a statement.
Bruce Broussard, US Oncology’s chairman and CEO, will lead McKesson’s
specialty care solutions business. He will report to Julian.
US Oncology will continue to operate under its brand name.
